Citadel Advisors’s Arbutus Biopharma ABUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.05M | Buy |
677,138
+572,295
| +546% | +$2.5M | ﹤0.01% | 5232 |
|
|
2025
Q4 | $504K | Sell |
104,843
-88,848
| -46% | -$400K | ﹤0.01% | 8997 |
|
|
2025
Q3 | $879K | Buy |
193,691
+73,419
| +61% | +$270K | ﹤0.01% | 7813 |
|
|
2025
Q2 | $372K | Sell |
120,272
-31,142
| -21% | -$103K | ﹤0.01% | 9321 |
|
|
2025
Q1 | $528K | Sell |
151,414
-126,145
| -45% | -$421K | ﹤0.01% | 8353 |
|
|
2024
Q4 | $908K | Sell |
277,559
-330,185
| -54% | -$1.21M | ﹤0.01% | 7242 |
|
|
2024
Q3 | $2.34M | Buy |
607,744
+462,869
| +319% | +$1.78M | ﹤0.01% | 5236 |
|
|
2024
Q2 | $448K | Sell |
144,875
-1,850,929
| -93% | -$5.55M | ﹤0.01% | 8277 |
|
|
2024
Q1 | $5.15M | Buy |
1,995,804
+61,846
| +3% | +$160K | ﹤0.01% | 3908 |
|
|
2023
Q4 | $4.83M | Sell |
1,933,958
-84,219
| -4% | -$165K | ﹤0.01% | 3843 |
|
|
2023
Q3 | $4.1M | Sell |
2,018,177
-278,995
| -12% | -$585K | ﹤0.01% | 3975 |
|
|
2023
Q2 | $5.28M | Buy |
2,297,172
+2,076,034
| +939% | +$5.4M | ﹤0.01% | 3571 |
|
|
2023
Q1 | $670K | Sell |
221,138
-145,722
| -40% | -$411K | ﹤0.01% | 7673 |
|
|
2022
Q4 | $855K | Buy |
366,860
+179,101
| +95% | +$428K | ﹤0.01% | 7116 |
|
|
2022
Q3 | $358K | Buy |
187,759
+105,406
| +128% | +$248K | ﹤0.01% | 9194 |
|
|
2022
Q2 | $223K | Sell |
82,353
-280,026
| -77% | -$717K | ﹤0.01% | 10467 |
|
|
2022
Q1 | $1.08M | Buy |
362,379
+23,631
| +7% | +$72.3K | ﹤0.01% | 7513 |
|
|
2021
Q4 | $1.32M | Sell |
338,748
-2,126
| -0.6% | -$8.26K | ﹤0.01% | 7219 |
|
|
2021
Q3 | $1.46M | Buy |
340,874
+229,943
| +207% | +$766K | ﹤0.01% | 7147 |
|
|
2021
Q2 | $336K | Sell |
110,931
-585,412
| -84% | -$1.81M | ﹤0.01% | 10991 |
|
|
2021
Q1 | $2.32M | Buy |
696,343
+597,446
| +604% | +$2.31M | ﹤0.01% | 6047 |
|
|
2020
Q4 | $351K | Buy |
98,897
+28,731
| +41% | +$101K | ﹤0.01% | 8785 |
|
|
2020
Q3 | $219K | Sell |
70,166
-1,280,189
| -95% | -$3.89M | ﹤0.01% | 8660 |
|
|
2020
Q2 | $2.46M | Sell |
1,350,355
-1,127,764
| -46% | -$1.85M | ﹤0.01% | 4197 |
|
|
2020
Q1 | $2.5M | Buy |
2,478,119
+2,423,126
| +4,406% | +$6.55M | ﹤0.01% | 3786 |
|
|
2019
Q4 | $153K | Buy |
+54,993
| New | +$89K | ﹤0.01% | 8351 |
|
|
2019
Q3 | – | Sell |
-11,959
| Closed | -$25K | – | 9084 |
|
|
2019
Q2 | $25K | Sell |
11,959
-2,266
| -16% | -$5.8K | ﹤0.01% | 8908 |
|
|
2019
Q1 | $51K | Buy |
+14,225
| New | +$54.6K | ﹤0.01% | 8807 |
|
|
2018
Q3 | – | Sell |
-78,617
| Closed | -$574K | – | 9141 |
|
|
2018
Q2 | $574K | Buy |
78,617
+13,820
| +21% | +$82.3K | ﹤0.01% | 6147 |
|
|
2018
Q1 | $324K | Buy |
64,797
+35,981
| +125% | +$191K | ﹤0.01% | 6622 |
|
|
2017
Q4 | $146K | Buy |
+28,816
| New | +$169K | ﹤0.01% | 7288 |
|
|
2017
Q3 | – | Sell |
-14,428
| Closed | -$52K | – | 7460 |
|
|
2017
Q2 | $52K | Buy |
14,428
+3,909
| +37% | +$13.4K | ﹤0.01% | 7082 |
|
|
2017
Q1 | $34K | Sell |
10,519
-27,629
| -72% | -$76.7K | ﹤0.01% | 7136 |
|
|
2016
Q4 | $93K | Buy |
+38,148
| New | +$111K | ﹤0.01% | 6701 |
|
|
2016
Q1 | – | Sell |
-269,245
| Closed | -$1.2M | – | 6637 |
|
|
2015
Q4 | $1.2M | Sell |
269,245
-485,385
| -64% | -$2.66M | ﹤0.01% | 3365 |
|
|
2015
Q3 | $4.6M | Buy |
754,630
+397,242
| +111% | +$3.52M | ﹤0.01% | 2026 |
|
|
2015
Q2 | $4.24M | Sell |
357,388
-3,137
| -0.9% | -$47.7K | ﹤0.01% | 2215 |
|
|
2015
Q1 | $6.29M | Buy |
360,525
+350,152
| +3,376% | +$7.17M | 0.01% | 1800 |
|
|
2014
Q4 | $157K | Buy |
10,373
+7,138
| +221% | +$123K | ﹤0.01% | 6244 |
|
|
2014
Q3 | $68K | Buy |
3,235
+657
| +25% | +$10.7K | ﹤0.01% | 6688 |
|
|
2014
Q2 | $34K | Buy |
+2,578
| New | +$36.6K | ﹤0.01% | 6999 |
|
Other funds holding ABUS
TSC
WCM
VCM
RCMNY
ACM
Citadel Advisors's ABUS Position: Q1 2026 in Review
Citadel Advisors increased its Arbutus Biopharma (ABUS) stake by 546% in Q1 2026, buying an estimated $2.5M and bringing the position to 677,138 shares worth $3.05M. The position accounts for ﹤0.01% of the portfolio, ranked #5232.
Citadel Advisors first reported a position in ABUS in Q2 2014 and has held it in 41 quarters since. The position peaked at $6.29M in Q1 2015. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.
- Citadel Advisors held 677,138 shares of Arbutus Biopharma worth $3.05M as of Q1 2026.
- Citadel Advisors bought 572,295 Arbutus Biopharma shares in Q1 2026, an estimated $2.5M.
- Arbutus Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5232 holding.
- Citadel Advisors first reported a position in Arbutus Biopharma in Q2 2014 and has held it in 41 quarters since.
- Citadel Advisors's Arbutus Biopharma position peaked at $6.29M in Q1 2015.
- 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.